| MicroRNAs, macrocontrol: regulation of miRNA processing I Slezak-Prochazka, S Durmus, BJ Kroesen, A van den Berg Rna 16 (6), 1087-1095, 2010 | 307 | 2010 |
| Oral Availability and Brain Penetration of the B-RAFV600E Inhibitor Vemurafenib Can Be Enhanced by the P-Glycoprotein (ABCB1) and Breast Cancer Resistance … S Durmus, RW Sparidans, E Wagenaar, JH Beijnen, AH Schinkel Molecular pharmaceutics 9 (11), 3236-3245, 2012 | 138 | 2012 |
| Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699) S Durmus, RW Sparidans, A Van Esch, E Wagenaar, JH Beijnen, ... Pharmaceutical research 32, 37-46, 2015 | 102 | 2015 |
| Apical ABC transporters and cancer chemotherapeutic drug disposition S Durmus, JJMA Hendrikx, AH Schinkel Advances in cancer research 125, 1-41, 2015 | 95 | 2015 |
| Hepatocellular shuttling and recirculation of sorafenib-glucuronide is dependent on Abcc2, Abcc3, and Oatp1a/1b A Vasilyeva, S Durmus, L Li, E Wagenaar, S Hu, AA Gibson, JC Panetta, ... Cancer research 75 (13), 2729-2736, 2015 | 73 | 2015 |
| Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer Ö Saatci, S Borgoni, Ö Akbulut, S Durmuş, U Raza, E Eyüpoğlu, C Alkan, ... Oncogene 37 (17), 2251-2269, 2018 | 66 | 2018 |
| Brain and testis accumulation of regorafenib is restricted by breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) A Kort, S Durmus, RW Sparidans, E Wagenaar, JH Beijnen, AH Schinkel Pharmaceutical research 32, 2205-2216, 2015 | 66 | 2015 |
| In vivo disposition of doxorubicin is affected by mouse Oatp1a/1b and human OATP1A/1B transporters S Durmus, J Naik, L Buil, E Wagenaar, O van Tellingen, AH Schinkel International journal of cancer 135 (7), 1700-1710, 2014 | 64 | 2014 |
| The impact of Organic Anion-Transporting Polypeptides (OATPs) on disposition and toxicity of antitumor drugs: Insights from knockout and humanized mice S Durmus, S van Hoppe, AH Schinkel Drug Resistance Updates 27, 72-88, 2016 | 52 | 2016 |
| Cationic Pd (II)/Pt (II) 5, 5-diethylbarbiturate complexes with bis (2-pyridylmethyl) amine and terpyridine: Synthesis, structures, DNA/BSA interactions, intracellular … C Icsel, VT Yilmaz, Y Kaya, S Durmus, M Sarimahmut, O Buyukgungor, ... Journal of inorganic biochemistry 152, 38-52, 2015 | 48 | 2015 |
| P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387 S Durmus, N Xu, RW Sparidans, E Wagenaar, JH Beijnen, AH Schinkel Pharmacological research 76, 9-16, 2013 | 47 | 2013 |
| Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug–Drug Interactions in Vivo S Durmus, G Lozano-Mena, A van Esch, E Wagenaar, O van Tellingen, ... Molecular pharmaceutics 12 (12), 4259-4269, 2015 | 34 | 2015 |
| P-glycoprotein, CYP3A, and plasma carboxylesterase determine brain and blood disposition of the mTOR Inhibitor everolimus (Afinitor) in mice SC Tang, RW Sparidans, KL Cheung, T Fukami, S Durmus, E Wagenaar, ... Clinical Cancer Research 20 (12), 3133-3145, 2014 | 34 | 2014 |
| Liquid chromatography–tandem mass spectrometric assay for the multikinase inhibitor regorafenib in plasma D Luethi, S Durmus, AH Schinkel, JHM Schellens, JH Beijnen, ... Biomedical Chromatography 28 (10), 1366-1370, 2014 | 29 | 2014 |
| Liquid chromatography–tandem mass spectrometric assay for the mutated BRAF inhibitor vemurafenib in human and mouse plasma RW Sparidans, S Durmus, AH Schinkel, JHM Schellens, JH Beijnen Journal of Chromatography B 889, 144-147, 2012 | 24 | 2012 |
| P-glycoprotein, CYP3A, and plasma carboxylesterase determine brain disposition and oral availability of the novel taxane cabazitaxel (Jevtana) in mice SC Tang, A Kort, KL Cheung, H Rosing, T Fukami, S Durmus, ... Molecular pharmaceutics 12 (10), 3714-3723, 2015 | 23 | 2015 |
| Liquid chromatography–tandem mass spectrometric assay for the PARP inhibitor rucaparib in plasma RW Sparidans, S Durmus, AH Schinkel, JHM Schellens, JH Beijnen Journal of pharmaceutical and biomedical analysis 88, 626-629, 2014 | 15 | 2014 |
| Liquid chromatography–tandem mass spectrometric assay for the mutated BRAF inhibitor dabrafenib in mouse plasma RW Sparidans, S Durmus, AH Schinkel, JHM Schellens, JH Beijnen Journal of Chromatography B 925, 124-128, 2013 | 15 | 2013 |
| Liquid chromatography–tandem mass spectrometry assay for the EGFR inhibitor pelitinib in plasma D Luethi, S Durmus, AH Schinkel, JHM Schellens, JH Beijnen, ... Journal of Chromatography B 934, 22-25, 2013 | 11 | 2013 |
| ABC transporters Mdr1a/1b, Bcrp1, Mrp2 and Mrp3 determine the sensitivity to PhIP/DSS-induced colon carcinogenesis and inflammation S Durmus, M Van der Valk, SF Teunissen, JY Song, E Wagenaar, ... Archives of toxicology 93, 775-790, 2019 | 9 | 2019 |
